Clinical Lab Expo exhibitor Genisphere has adapted its 3DNA Dendrimer Signal Amplification technology for lateral flow (LF) point-of-care (POC) assays, providing improved sensitivity and enabling a broad new array of POC tests. The technology reportedly will enable the commercialization of new LF assays that otherwise could not be launched because of unacceptably low sensitivity and will help test makers differentiate themselves in the competitive POC testing market. Manufacturers can drop the reagent into existing bioassay platforms with minimal adaptation.

The proprietary 3DNA Dendrimer technology has delivered up to 64-fold improvements in sensitivity over standard, nondendrimer assays, says the company. With this heightened power of detection, the technology can reduce false negatives and significantly increase accuracy of otherwise subjective outcome readings. (A technical note is available for download.)

The technology will expand the POC market to more-sensitive rapid testing for a wide list of conditions such as infectious diseases, bacterial sepsis, coronary biomarkers, food microbiological testing, and environmental and water testing that are outside the analytical reach of current systems, says Genisphere.

Visit the company at booth 246.